Diagnostic accuracy of b800 and b1500 DWI-MRI of the pelvis to detect residual rectal adenocarcinoma: a multi-reader study

  • David D. B. BatesEmail author
  • Jennifer S. Golia Pernicka
  • James L. FuquaIII
  • Viktoriya Paroder
  • Iva Petkovska
  • Junting Zheng
  • Marinela Capanu
  • Juliana Schilsky
  • Marc J. Gollub
Hollow Organ GI



To compare the sensitivity, specificity and intra-observer and inter-observer agreement of pelvic magnetic resonance imaging (MRI) b800 and b1500 s/mm2 sequences in the detection of residual adenocarcinoma after neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC).


Detection of residual adenocarcinoma after neoadjuvant CRT for LARC has become increasingly important and relies on both MRI and endoscopic surveillance. Optimal MRI diffusion b values have yet to be established for this clinical purpose.


From our MRI database between 2018 and 2019, we identified a cohort of 28 patients after exclusions who underwent MRI of the rectum before and after neoadjuvant chemoradiation with a protocol that included both b800 and b1500 s/mm2 diffusion sequences. Four radiologists experienced in rectal MRI interpreted the post-CRT MRI studies with either b800 DWI or b1500 DWI, and a minimum of 2 weeks later re-interpreted the same studies using the other b value sequence. Surgical pathology or endoscopic follow-up for 1 year without tumor re-growth was used as the reference standard. Descriptive statistics compared accuracy for each reader and for all readers combined between b values. Inter-observer agreement was assessed using kappa statistics. A p value of 0.05 or less was considered significant.


Within the cohort, 19/28 (67.9%) had residual tumor, while 9/28 (32.1%) had a complete response. Among four readers, one reader had increased sensitivity for detection of residual tumor at b1500 s/mm2 (0.737 vs. 0.526, p = 0.046). There was no significant difference between detection of residual tumor at b800 and at b1500 for the rest of the readers. With all readers combined, the pooled sensitivity was 0.724 at b1500 versus 0.605 at b800, but this was not significant (p = 0.119). There was no difference in agreement between readers at the two b value settings (67.8% at b800 vs. 72.0% at b1500), or for any combination of individual readers.


Aside from one reader demonstrating increased sensitivity, no significant difference in accuracy parameters or inter-observer agreement was found between MR using b800 and b1500 for the detection of residual tumor after neoadjuvant CRT for LARC. However, there was a suggestion of a trend towards increased sensitivity with b1500, and further studies using larger cohorts may be needed to further investigate this topic.


Rectal cancer MRI Diffusion weighted imaging b value Chemoradiation 



  1. 1.
    Napoletano M, Mazzucca D, Prosperi E, Aisa MC, Lupattelli M, Aristei C, Scialpi M (2019) Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy. Abdom Radiol (NY). CrossRefGoogle Scholar
  2. 2.
    Amodeo S, Rosman AS, Desiato V, Hindman NM, Newman E, Berman R, Pachter HL, Melis M (2018) MRI-Based Apparent Diffusion Coefficient for Predicting Pathologic Response of Rectal Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis. AJR Am J Roentgenol 211 (5):W205-W216. CrossRefGoogle Scholar
  3. 3.
    De Felice F, Magnante AL, Musio D, Ciolina M, De Cecco CN, Rengo M, Laghi A, Tombolini V (2017) Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Eur J Surg Oncol 43 (7):1324-1329. CrossRefGoogle Scholar
  4. 4.
    Blazic IM, Lilic GB, Gajic MM (2017) Quantitative Assessment of Rectal Cancer Response to Neoadjuvant Combined Chemotherapy and Radiation Therapy: Comparison of Three Methods of Positioning Region of Interest for ADC Measurements at Diffusion-weighted MR Imaging. Radiology 282 (2):418-428. CrossRefGoogle Scholar
  5. 5.
    Foti PV, Privitera G, Piana S, Palmucci S, Spatola C, Bevilacqua R, Raffaele L, Salamone V, Caltabiano R, Magro G, Li Destri G, Milone P, Ettorre GC (2016) Locally advanced rectal cancer: Qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapy. Eur J Radiol Open 3:145-152. CrossRefGoogle Scholar
  6. 6.
    Cai PQ, Wu YP, An X, Qiu X, Kong LH, Liu GC, Xie CM, Pan ZZ, Wu PH, Ding PR (2014) Simple measurements on diffusion-weighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol 24 (11):2962-2970. CrossRefGoogle Scholar
  7. 7.
    Lu W, Jing H, Ju-Mei Z, Shao-Lin N, Fang C, Xiao-Ping Y, Qiang L, Biao Z, Su-Yu Z, Ying H (2017) Intravoxel incoherent motion diffusion-weighted imaging for discriminating the pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Sci Rep 7 (1):8496.
  8. 8.
    Yu J, Xu Q, Song JC, Li Y, Dai X, Huang DY, Zhang L, Li Y, Shi HB (2017) The value of diffusion kurtosis magnetic resonance imaging for assessing treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol 27 (5):1848-1857. CrossRefGoogle Scholar
  9. 9.
    Joye I, Deroose CM, Vandecaveye V, Haustermans K (2014) The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol 113 (2):158-165. CrossRefGoogle Scholar
  10. 10.
    Adubeiro N, Nogueira ML, Nunes RG, Ferreira HA, Ribeiro E, La Fuente JMF (2018) Apparent diffusion coefficient in the analysis of prostate cancer: determination of optimal b value pair to differentiate normal from malignant tissue. Clin Imaging 47:90-95. CrossRefGoogle Scholar
  11. 11.
    Agarwal HK, Mertan FV, Sankineni S, Bernardo M, Senegas J, Keupp J, Daar D, Merino M, Wood BJ, Pinto PA, Choyke PL, Turkbey B (2017) Optimal high b value for diffusion-weighted MRI in diagnosing high risk prostate cancers in the peripheral zone. J Magn Reson Imaging 45 (1):125-131. CrossRefGoogle Scholar
  12. 12.
    Manenti G, Nezzo M, Chegai F, Vasili E, Bonanno E, Simonetti G (2014) DWI of Prostate Cancer: Optimal b Value in Clinical Practice. Prostate Cancer 2014:868269. CrossRefGoogle Scholar
  13. 13.
    Tamura T, Murakami S, Naito K, Yamada T, Fujimoto T, Kikkawa T (2014) Investigation of the optimal b value to detect breast tumors with diffusion-weighted imaging by 1.5-T MRI. Cancer Imaging 14:11.
  14. 14.
    Karki K, Hugo GD, Ford JC, Olsen KM, Saraiya S, Groves R, Weiss E (2015) Estimation of optimal b value sets for obtaining apparent diffusion coefficient free from perfusion in non-small cell lung cancer. Phys Med Biol 60 (20):7877-7891. CrossRefGoogle Scholar
  15. 15.
    Kaya B, Koc Z (2014) Diffusion-weighted MRI and optimal b value for characterization of liver lesions. Acta Radiol 55 (5):532-542. CrossRefGoogle Scholar
  16. 16.
    Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, Fenlon HM, Gollub MJ, Gourtsoyianni S, Halligan S, Hoeffel C, Kim SH, Laghi A, Maier A, Rafaelsen SR, Stoker J, Taylor SA, Torkzad MR, Blomqvist L (2018) Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 28 (4):1465-1475. CrossRefGoogle Scholar
  17. 17.
    Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, Petkovska I, Gollub MJ (2019) MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management. Radiographics 39 (2):367-387. CrossRefGoogle Scholar
  18. 18.
    Wei IH, Garcia-Aguilar J (2018) Non-operative management of rectal cancer: understanding tumor biology. Minerva Chir 73 (6):601-618.
  19. 19.
    Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, Guillem JG, Paty PB, Avila K, Garcia-Aguilar J, Rectal Cancer C (2015) Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 15:767.
  20. 20.
    Maas M, Lambregts DM, Nelemans PJ, Heijnen LA, Martens MH, Leijtens JW, Sosef M, Hulsewe KW, Hoff C, Breukink SO, Stassen L, Beets-Tan RG, Beets GL (2015) Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment. Ann Surg Oncol 22 (12):3873-3880. CrossRefGoogle Scholar
  21. 21.
    Koo JH, Kim CK, Choi D, Park BK, Kwon GY, Kim B (2013) Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: optimal B value at 3T. Korean J Radiol 14 (1):61-69. CrossRefGoogle Scholar
  22. 22.
    Cercek A, Goodman KA, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL, Stadler ZK, Wu AJ, Weiser MR, Paty PB, Guillem JG, Nash GM, Temple LK, Garcia-Aguilar J, Saltz LB (2014) Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 12 (4):513-519CrossRefGoogle Scholar
  23. 23.
    Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silva e Sousa AH, Jr., Campos FG, Kiss DR, Gama-Rodrigues J (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240 (4):711-717; discussion 717-718.
  24. 24.
    Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R (2008) Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol 56 (1):45-50. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • David D. B. Bates
    • 1
    Email author
  • Jennifer S. Golia Pernicka
    • 1
  • James L. FuquaIII
    • 1
  • Viktoriya Paroder
    • 1
  • Iva Petkovska
    • 1
  • Junting Zheng
    • 2
  • Marinela Capanu
    • 2
  • Juliana Schilsky
    • 1
  • Marc J. Gollub
    • 1
  1. 1.Department of RadiologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Epidemiology & BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations